Abstract 1733P
Background
On 24th of February 2022 reality in Ukraine changed. Ukraine became a victim of unfair attack of the neighbouring county. It influenced civilian population hugely, including the most vulnerable - children, elderly and patients. Since then, cancer patients became fighters of two fights - malignant disease and external aggressor. After more than a year of this reality Ukrainian oncologists would like to remind international society that the problem is not solved, and Ukrainians desperately need support.
Methods
It is generalized description of situation in the sphere of oncology in Ukraine since 24th of February 2022.
Results
According to Ukraine's Minister of Health, Victor Lyashko, during the first year of the war in Ukraine 1218 hospitals were damaged, 540 - partially destroyed and 173 destroyed completely. Among them - oncological hospitals. More than a million (∼1.2) Ukrainians currently stay on temporary occupied territories of the country and do not have access to qualified medical care. Around 7 million people had to move to safer areas of the country to stay safe and thousands of cancer patients had to move abroad for further treatment. It influenced the oncological landscape significantly. Oncological centers currently have to deal with 70% more patients than before the war. Moreover, the quantity of advanced stage disease has risen dramatically because a lot of people just couldn’t get medical help in time. Therefore, it caused bigger pressure on the medical system, requiring even more resources when they are so limited. At the same time, all clinical trials were put on pause leaving patients with advanced and rare diseases with no options for further treatment. Luckily, international society is extremely friendly to Ukraine providing Ukrainians with shelters and supplies, both material and intellectual. It helped and is helping a lot. But unfortunately, war is not over, and help is still needed.
Conclusions
The aim of the work is to show how things were going during this year of war and how they are actually going now for word to realize that even during the hardest time there is a place for high quality medical care. That only became possible thanks to huge support of international society, but there is still a lot to do to rebuild and improve reality that was destroyed on 24th of February.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
The authors.
Funding
Has not received any funding.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
1716P - Addressing clinical trial disparities in Spain: A digital solution
Presenter: Max Hardy-Werbin
Session: Poster session 23
1717P - Management of patients during a digital healthcare record system transition: A phase I unit experience
Presenter: Lyra Del Rosario
Session: Poster session 23
1718P - Impact of the economic status of the patient's country of residence on the outcome of oncology clinical trials
Presenter: Saki Nishiyama
Session: Poster session 23
1719P - Decentralized clinical trials: Is there a space in Italy?
Presenter: Celeste Cagnazzo
Session: Poster session 23
1720P - Experience in the provision of oncology services immediately after a major disaster
Presenter: Burak Aktas
Session: Poster session 23
1721P - Self-assessment tool and best-practice sharing to support hospitals in improving the quality of multi-disciplinary teams in lung cancer care
Presenter: Ernest Nadal
Session: Poster session 23
1722P - Factors contributing to differences in evidence compliance rate in cancer treatment among second opinion cases
Presenter: Tomomi Sanomachi
Session: Poster session 23
1723P - Improving access to molecular tumour boards for complex genomic profiles: A healthcare policy from the Netherlands
Presenter: Sahar van Waalwijk van Doorn-Khosrovani
Session: Poster session 23
1724P - Improving access to breast cancer diagnosis and treatment through navigation: Evaluation of a one-year pilot project in Botswana
Presenter: Ariane Migeotte
Session: Poster session 23
1725P - Genetic counselling for cancer in EU member states: Review and foundation for consensus recommendations
Presenter: J. Matt McCrary
Session: Poster session 23